This article is not intended to provide medical information or medical advice.
On November 25, 2019, my father was hospitalized.
The initial diagnosis was pneumonia. If it had been common community-acquired pneumonia, antibiotics would likely have helped. We all assumed he might simply need a slightly longer hospital stay.
But he did not improve even after his medication was changed. Some time later, we learned that the underlying diagnosis was interstitial pneumonia.
When fibrosis progresses in interstitial pneumonia, reversing the resulting changes becomes difficult. Once the lungs become stiff, they do not readily regain their flexibility. Even today, there is no easy way to fundamentally treat the condition.[1]
Even so, my family believed that my father would gradually get better. Every day, I checked the oxygen level in his blood (SpO2) on the monitor beside his bed. It became part of my daily routine.
The number kept falling.
On December 13, my father passed away—18 days after he had been admitted to the hospital.
Three months later, my elder daughter was born. She would have been my father’s first grandchild. I was not able to let him hold her, or see the gentle smile he rarely showed me.
Beyond Next Ventures recently invested as the lead investor in PulmoGate, a medical AI startup originating from Nagoya University.
Interstitial Lung Disease Still Presents a Major Diagnostic Challenge
Interstitial lung disease is a broad term for conditions involving inflammation and fibrosis in the interstitium of the lungs. Idiopathic pulmonary fibrosis (IPF), in particular, can progress rapidly and may suddenly worsen after what initially appears to be a minor trigger, such as a common cold. This is known as an acute exacerbation.[1]
Yet the disease is difficult to diagnose. Its symptoms and imaging findings often resemble those of other lung conditions. For this reason, clinical guidelines recommend a multidisciplinary discussion (MDD), in which several specialists review and discuss each case together. However, relatively few medical institutions are able to assemble such a team in-house.[2]
In my father’s case, I do not know whether an earlier diagnosis would have changed the outcome. I am not suggesting that it necessarily would have. But the thought that there might have been a way to reach the right diagnosis sooner has stayed with me ever since that winter.
This is the diagnostic gap that PulmoGate is addressing. The company aims to make specialist knowledge available beyond the walls of individual institutions and to improve the quality and consistency of diagnosis. That could help patients and their families reach appropriate treatment sooner.
Meeting Dr. Taiki Furukawa
I first met Dr. Taiki Furukawa, a pulmonologist, on November 17, 2021, through an introduction from Nagoya University.
To be honest, my first impression was: “What an impressive doctor.” He had the polished presence of someone who had stepped straight out of a medical drama. Standing next to me made the contrast rather obvious (laughs).
What surprised me was what came next.
Dr. Furukawa trained in clinical practice at Tosei General Hospital, which is known for its expertise in interstitial pneumonia, and also conducted AI research at RIKEN. He supported the operation of the nationwide PROMISE clinical study, which began in 2020. By the end of 2022, the study had enrolled 2,812 cases from 223 medical institutions.[3] He has also served as a member of a task force of the Japanese Respiratory Society examining insurance coverage for MDD, helping advance the development of a certification system and efforts toward reimbursement.[3]
One clinician had helped bring together academic societies, healthcare systems, and hospitals across Japan to run a project of this scale. I was honestly overwhelmed.
What mattered was that Dr. Furukawa was not simply proposing a diagnostic service that happened to use AI. He was rethinking and standardizing the diagnostic process itself: what information specialists should review, how they should discuss it, and what criteria they should use in reaching a decision.
Dr. Furukawa later applied to the Tongali GAP Fund to pursue commercialization and was selected. Since the program’s STEP2 stage, Beyond Next Ventures has supported the project as its commercialization partner. Turning research into a business requires more than technology. It requires an understanding of clinical needs and the ability to build connections with healthcare institutions and the healthcare system. PulmoGate has demonstrated that kind of drive.
An Entrepreneur Who Can Turn Research into a Business
Bringing research into clinical practice also requires a strong business leader. PulmoGate’s representative director and CEO is Tomo Tominaga.
After working at two global consulting firms, Tominaga joined NK Medico (now Premedica) in 2012 and built its preventive healthcare business from the ground up. Its flagship offering was LOX-index, a blood test that estimates the risk of stroke and myocardial infarction. More than 4,800 medical institutions have adopted services including LOX-index, and more than 1.5 million people have used them. I often see the test myself when I go for a health checkup.
In April 2024, Premedica was acquired in full by Medipal Holdings, a major pharmaceutical wholesaler, for ¥3.8 billion. Tominaga is a serial entrepreneur who has experienced the full arc of building, scaling, and selling a business.
Over the past 16 years, I have invested in university-originated startups. I have seen an era when professors and researchers took on the CEO role themselves, followed by an era when business professionals became CEOs while researchers focused on technology. We are now entering a period in which entrepreneurs who have already built, organized, financed, and sold a business are choosing deep tech as their next challenge.
The value of this shift is not the label “serial entrepreneur” itself. It is the practical experience that comes with it. When that experience in hiring, fundraising, organization-building, customer development, and exits is combined with technology that researchers have refined over many years, the path from research to commercialization may become shorter.
Dr. Furukawa brings clinical and research expertise, while Tominaga leads commercialization and organizational development. The fact that these two leaders bring different areas of expertise to the same challenge is one of PulmoGate’s greatest strengths.
Connecting One Disease from Diagnosis through Rehabilitation
I see another opportunity in PulmoGate’s model: focusing on interstitial lung disease and supporting the patient journey continuously from diagnosis through treatment and rehabilitation. I have long believed that models focused on a specific disease and designed to support the patient’s journey as a whole will become increasingly important.
Hinge Health in the United States is a prominent example. The company focuses on musculoskeletal pain in areas such as the back and knees, combining online exercise therapy with wearable devices to support patients from acute pain through postoperative rehabilitation. Its May 2025 IPO drew attention as one of the largest venture-backed healthtech IPOs in the United States since 2021.[4] Hinge Health reported revenue of $588 million in 2025, up 51% year on year,[5] and its market capitalization exceeded ¥1 trillion as of mid-October 2026.[6]
The market size and healthcare systems are different from those surrounding interstitial lung disease. Even so, the idea of continuing to support patients after diagnosis and expanding the range of care over time is highly relevant to PulmoGate. I see three reasons why this model may work across different fields.
First, the constraints of place are beginning to ease.
Diagnosis, treatment, and rehabilitation have traditionally been separated because the specialists and equipment required for each were located in different places. A patient’s journey was divided by how far they could travel.
That premise is changing. In Japan, the 2022 revision of the medical fee schedule made online consultations available on a permanent basis from the initial visit.[5] CT images can be shared across institutions through the cloud, and pulse oximeters are now commonly used at home. The SpO2 readings I checked every day on my father’s hospital monitor could now be measured at home and shared with a primary physician. The PROMISE study has also demonstrated a working model for connecting 223 medical institutions and specialists online, making limited specialist expertise available nationwide.[3]
Second, the value of data increases when it remains connected.
In interstitial lung disease, diagnosis and treatment cannot be separated. The appropriate treatment depends on the type of disease. In IPF, a clinical trial reported that a combination of prednisone, azathioprine, and N-acetylcysteine—treatments used for other forms of interstitial pneumonia—increased death and hospitalization compared with a placebo.[6] An incorrect diagnosis can therefore lead to treatment that, despite the best intentions, may harm the patient.
If diagnosis, treatment, and subsequent outcomes can be connected, it becomes possible to learn which treatments work for which patients. The clinical value and the business value can then move in the same direction, as providers support patients over a longer period and accumulate valuable data.
Third, the model creates room to expand.
Diagnosis is the starting point of a patient’s journey. Which medication should be used? Is home oxygen needed? How often should rehabilitation be provided? These decisions follow from the initial diagnosis. By building trust with medical professionals and establishing a relationship with patients at that entry point, a company can expand into treatment choices, rehabilitation, and monitoring. A one-time diagnostic service can evolve into a longer-term model of care. Hinge Health, for example, began with sensors and an app for knee pain and has since expanded into prevention, postoperative rehabilitation, women’s pelvic health, and fall prevention.[7]
PulmoGate plans to begin with remote MDD, in which specialists review cases online. It aims to use data from the PROMISE study to support diagnosis and treatment selection with AI, and then extend its support to home oxygen therapy, rehabilitation, and monitoring. The company is also advancing a collaboration with Teijin Pharma, which has experience in home oxygen therapy. A survey cited by the company found that 96% of the hospitals surveyed would like to use remote MDD.
The AI-based support for diagnosis and treatment selection remains in the research and development stage and has not received medical-device approval. PulmoGate is not proposing to deliver all of these services as a single package from day one. The plan is to establish diagnosis as the entry point, accumulate knowledge and data there, and gradually expand into areas that support patients afterward. I find that phased approach both realistic and promising from a business perspective.
PulmoGate’s vision—to create a global standard for personalized medicine in respiratory care—lies beyond these steps.
A Quiet Tension before the Investment Committee
In truth, I did not feel uncertain about the investment itself. Since meeting Dr. Furukawa in 2021, I had been involved in preparing to launch the company, almost as one of its members. Building a company with researchers from the research stage onward is what we at Beyond Next Ventures call “company creation,” and it is an important part of our work.
What made me nervous was something else. At Beyond Next Ventures, the person responsible for an investment cannot make the decision alone. After meetings with our partners, we need their agreement at the investment committee before the company can move forward. I trusted the team, but would the other partners see the same potential? Would they be willing to take on this challenge as a firm?
Before I knew it, I was sitting there feeling less like an investor and more like someone seeking investment.
Tominaga and Dr. Furukawa did more than explain the business. They carefully laid out how they intended to address this social challenge and build a company capable of making an impact globally. They did not gloss over the difficulties. Their answers came from people who had been working on those difficulties for years. Watching the management team respond, I felt slightly embarrassed that I had worried—and also felt myself sit up straighter.
Why We Invested in PulmoGate
To summarize, there are three main reasons we decided to invest in PulmoGate.
First, interstitial lung disease still leaves significant room to make specialist knowledge available where it is needed and to align diagnostic standards. PulmoGate is building that system from the needs of clinical practice.
Second, the company has a team capable of combining clinical and research expertise with commercialization. Dr. Furukawa brings deep experience in clinical practice and research, while Tominaga has built, scaled, and sold a business.
Third, PulmoGate is aiming to connect the patient journey beyond a one-time diagnosis, linking diagnosis with treatment, home oxygen therapy, rehabilitation, and monitoring. The idea of using data from diagnosis to support the next stage of care has significant potential in both clinical and business terms.
Teijin Pharma, Mitsubishi UFJ Capital, and STATION Ai also participated in this seed round. Together with these strong partners, we hope to support PulmoGate as it works to bring its research from the development stage into clinical practice.
For More Time with Family
Illness does not affect only the patient. It affects family members, friends, loved ones, and colleagues. I learned that firsthand that winter.
I want to reduce the number of people who go through an experience like mine.
That is why I want to support and help build medical technologies that can save the people closest to us. If I or someone in my family becomes ill someday, I hope to be helped by a medical device that I helped finance and bring into practice. It may sound self-centered, but that is how I honestly feel.
It will soon be seven years since my father passed away. In that winter, all I could do was watch the numbers on his monitor. Today, I am in a position to support, as an investor, a company working to address the same disease.
I hope the system PulmoGate is building will one day help extend a family’s time together, even if only a little. I look forward to continuing this journey with Dr. Furukawa, Tominaga, and everyone at PulmoGate.
Sources
-
● Sources
- [1] Nanbyo Information Center, “Idiopathic Interstitial Pneumonia (Designated Intractable Disease 85),” https://www.nanbyou.or.jp/entry/156
- [2] Japanese Respiratory Society, Guide to the Diagnosis and Treatment of Idiopathic Interstitial Pneumonia 2022 (4th revised edition).
- [3] PROMISE and IBiS research portal, https://portal.mdd.systems/greeting/; Furukawa T, et al., BMC Pulmonary Medicine, 2024 (UMIN000040678).
- [4] Morningstar, “Hinge Health Sparks Hope with 17% IPO Pop in NYSE Debut,” May 2025; PitchBook, “Hinge Health Breaks IPO Logjam,” Q2 2025.
- [7] Ministry of Health, Labour and Welfare, “FY2022 Revision of the Medical Fee Schedule” (permanent approval of online consultations from the initial visit).
- [8] Raghu G, et al., “Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis,” New England Journal of Medicine, 2012;366:1968–77 (PANTHER-IPF trial).
- [9] Hinge Health, “10 years in and we’re just getting started,” https://es.hingehealth.com/resources/press-releases/10-years-in-and-were-just-getting-started; Contrary Research, “Hinge Health,” https://research.contrary.com/company/hingehealth.



